April 24, 2020 / 12:32 PM / a month ago

BRIEF-Tracon Pharmaceuticals Retains Global Rights To Trc253 Following Completion Of A Phase 1/2 Trial

April 24 (Reuters) - TRACON Pharmaceuticals Inc:

* TRACON PHARMACEUTICALS RETAINS GLOBAL RIGHTS TO TRC253 FOLLOWING COMPLETION OF A PHASE 1/2 TRIAL

* TRACON PHARMACEUTICALS - RETAINED GLOBAL RIGHTS TO TRC253 BASED ON JANSSEN’S DECISION NOT TO EXERCISE ITS OPTION TO REACQUIRE GLOBAL RIGHTS TO TRC253

* TRACON PHARMACEUTICALS - DOES NOT EXPECT TO DEVOTE FURTHER RESOURCES TO DEVELOPING TRC253 ABSENT ESTABLISHING A PARTNERSHIP IN CHINA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below